Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Czech National Bank boosted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 6.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange ...

CWA Asset Management Group LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 11.9% in ...

Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

With the close of 2024 and the launch of a new year, we can take a moment to look back at what was another eventful, ...

Topline data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of 22.8%.

In their respective phase 3 trials ... I remain bullish on Eli Lilly’s long-term growth prospects and expect the company will be able to meet or exceed long-term expectations, but relative ...

Orbis Medicines has raised €90m ($94m) in Series A funding to advance the development of its next-generation orally dosable macrocycle drugs.